Heritage Pharmaceuticals Recalls Colistimethate Sodium Injection Due to Sterility Concerns
Heritage Pharmaceuticals is recalling Colistimethate Sodium Injection due to quality control concerns regarding sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. Per the rubric, FDA Class II recalls with potential for adverse health consequences (such as sterility issues in injectables) are classified as Severe (Score 4), as they are not Class I but involve significant risk.
Plain-English summary
Heritage Pharmaceuticals, Inc. is recalling Colistimethate Sodium for Injection USP, 150 mg per vial, due to concerns with quality control processes that affect the assurance of sterility. The product is a prescription-only injectable medication manufactured by Emcure Pharmaceuticals Ltd. in India for Heritage Pharmaceuticals Inc.
The recall covers specific lots of the product with expiration dates ranging from September 2014 to October 2016. The distribution pattern is listed as nationwide. The source text does not specify the number of units recalled or report any illnesses or injuries associated with the product.
Consumers and healthcare providers should stop using the affected lots and contact their healthcare provider or the recalling firm for further instructions. The recall is classified as FDA Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- COLISTIMETHATE SODIUM (COLISTIMETHATE SODIUM)
- Brand
- COLISTIMETHATE SODIUM
- Manufacturer
- Heritage Pharmaceuticals, Inc.
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (18)
- Lot # VCOA002
- Exp. 09/14
- VCOA003
- Exp. 10/14
- VCOA004
- Exp. 10/14 VCOA005
- Exp. 01/15
- VCOA006
- Exp 03/15
- VCOA007
- Exp 09/15
- VCOA008
- Exp. 12/15
- VCOA009
- Exp. 02/16
- VCOA010
- Exp. 10/16 VCOA011
- Exp. 10/16
UPCs (1)
- 0323155193312
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Heritage Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Heritage Pharmaceuticals, Inc.
See all →- ModerateHeritage Pharmaceuticals Recalls Clindamycin Palmitate Hydrochloride Due to Foreign Particles
FDA (Drugs) · 2026-08-19
- HighDesipramine 25 mg tablets recalled over nitrosamine impurity above intake limit
FDA (Drugs) · 2025-11-05
- HighDesipramine 75 mg tablets recalled over nitrosamine impurity above intake limit
FDA (Drugs) · 2025-11-05
- HighDesipramine tablets recalled over nitrosamine impurity above acceptable daily intake
FDA (Drugs) · 2025-11-05
- HighDesipramine 50 mg tablets recalled over nitrosamine impurity above intake limit
FDA (Drugs) · 2025-11-05
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereHeritage Pharmaceuticals Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-05-29
- SevereHeritage Pharmaceuticals Recalls Cidofovir Injection Due to Sterility Concerns
FDA (Drugs) · 2019-01-16
- HighHeritage Pharmaceuticals Recalls Subpotent Etomidate Injection Vials
FDA (Drugs) · 2019-03-27
- SevereHeritage Pharmaceuticals Recalls Cidofovir Dihydrate Injection Due to Sterility Concerns
FDA (Drugs) · 2018-10-31
- CriticalHeritage Pharmaceuticals Recalls Amikacin Sulfate Injection Due to Microbial Growth
FDA (Drugs) · 2019-06-19
- CriticalHeritage Pharmaceuticals Recalls Prochlorperazine Edisylate Injection Due to Microbial Growth
FDA (Drugs) · 2019-06-19